These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 10831272)

  • 1. Combined chemoimmunotherapy in metastatic melanoma--is there a need for the double?
    Schrader AJ
    Anticancer Drugs; 2000 Mar; 11(3):143-8. PubMed ID: 10831272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemotherapy of melanoma.
    Keilholz U
    Forum (Genova); 2003; 13(2):158-65; quiz 189. PubMed ID: 14732882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma.
    Flaherty LE
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S15-20. PubMed ID: 10685653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemotherapy for advanced melanoma.
    Keilholz U; Gore ME
    Semin Oncol; 2002 Oct; 29(5):456-61. PubMed ID: 12407510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The treatment of metastatic melanoma with chemotherapy and biologics.
    Atkins MB
    Curr Opin Oncol; 1997 Mar; 9(2):205-13. PubMed ID: 9161801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma.
    Sasse AD; Sasse EC; Clark LG; Ulloa L; Clark OA
    Cochrane Database Syst Rev; 2007 Jan; (1):CD005413. PubMed ID: 17253556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemotherapy of melanoma.
    Flaherty LE; Gadgeel SM
    Semin Oncol; 2002 Oct; 29(5):446-55. PubMed ID: 12407509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving survival in patients with high-risk and metastatic melanoma: immunotherapy leads the way.
    Agarwala S
    Am J Clin Dermatol; 2003; 4(5):333-46. PubMed ID: 12688838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of metastatic melanoma: an overview.
    Bhatia S; Tykodi SS; Thompson JA
    Oncology (Williston Park); 2009 May; 23(6):488-96. PubMed ID: 19544689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-2-based immunotherapy and chemoimmunotherapy in metastatic melanoma.
    Keilholz U; Scheibenbogen C; Brossart P; Möhler T; Tilgen W; Hunstein W
    Recent Results Cancer Res; 1995; 139():383-90. PubMed ID: 7597305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WITHDRAWN: Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma.
    Sasse AD; Sasse EC; Clark LG; Clark OAC
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD005413. PubMed ID: 29409139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy and chemoimmunotherapy for metastatic malignant melanoma: review and recent advances.
    Khayat D; Coeffic D
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():238-47. PubMed ID: 10895160
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of metastasized malignant melanoma].
    Kamanabrou D
    Praxis (Bern 1994); 2001 Mar; 90(10):391-6. PubMed ID: 11305184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy.
    Anderson CM; Buzaid AC; Sussman J; Lee JJ; Ali-Osman F; Braunschweiger PG; Plager C; Bedikian A; Papadopoulos N; Eton O; Legha SS; Grimm EA
    Melanoma Res; 1998 Apr; 8(2):149-55. PubMed ID: 9610868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of metastatic malignant melanoma.
    Atallah E; Flaherty L
    Curr Treat Options Oncol; 2005 May; 6(3):185-93. PubMed ID: 15869730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of interferon alfa in the treatment of metastatic melanoma.
    Legha SS
    Semin Oncol; 1997 Feb; 24(1 Suppl 4):S24-31. PubMed ID: 9122731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study.
    Dorval T; Négrier S; Chevreau C; Avril MF; Baume D; Cupissol D; Oskam R; de Peuter R; Vinke J; Herrera A; Escudier B
    Cancer; 1999 Mar; 85(5):1060-6. PubMed ID: 10091789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment for metastatic malignant melanoma: old drugs and new strategies.
    Mouawad R; Sebert M; Michels J; Bloch J; Spano JP; Khayat D
    Crit Rev Oncol Hematol; 2010 Apr; 74(1):27-39. PubMed ID: 19781957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic treatments for advanced cutaneous melanoma.
    Anderson CM; Buzaid AC; Legha SS
    Oncology (Williston Park); 1995 Nov; 9(11):1149-58; discussion 1163-4, 1167-8. PubMed ID: 8703684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
    Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
    J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.